This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
This article relies excessively on references to primary sources. Please improve this article by adding secondary or tertiary sources. Find sources: "Kite Pharma" – news · newspapers · books · scholar · JSTOR(August 2018) (Learn how and when to remove this message)
This article contains content that is written like an advertisement. Please help improve it by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view.(August 2018) (Learn how and when to remove this message)
Kite Pharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous CAR T cell therapy, a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
^ ab"Kite Pharma LEADERSHIP". March 10, 2023. Archived from the original on March 10, 2023. Retrieved March 10, 2023.
^Cite error: The named reference board was invoked but never defined (see the help page).
^ abCite error: The named reference Wright2020 was invoked but never defined (see the help page).
KitePharma is an American biotechnology company that develops cancer immunotherapy products, with a primary focus on genetically engineered autologous...
president and CEO of KitePharma. Although founded in 2009, the company went public in June 2014. Based in Santa Monica, KitePharma is a commercial-stage...
million in 2015. In August 2017, the company announced it would acquire KitePharma for $11.9 billion, equating to $180 cash per share, a 29% premium over...
"KitePharma, Inc. Completes $50 Million Mezzanine Private Financing". MarketWatch. April 28, 2014. Retrieved April 29, 2014. "KitePharma (KITE) Files...
leukemia (B-ALL), and axicabtagene ciloleucel (Yescarta), marketed by KitePharma originally for diffuse large B-cell lymphoma (DLBCL). There are now six...
real estate, biotech and tech start ups. Investments include ZipCar, KitePharma and Heal. In 2013, she bought a 22-acre vineyard estate in Napa Valley...
a clinical recommendation for routine CFTR gene therapy. In February KitePharma announced results from a clinical trial of CAR-T cells in around a hundred...
in Santa Monica at the Pen Factory (a former Paper Mate factory) from KitePharma, which had leased the space from Lincoln Property Company. With the acquisition...
to include T cell malignancies. It was developed by California-based KitePharma. Axicabtagene ciloleucel was awarded U.S. Food and Drug Administration...
Markit Arie S. Belldegrun (1949–), Israeli-American (co-)founder of KitePharma and biotechnology companies Agensys, Allogene Therapeutics Howard Birndorf...
the original on September 25, 2014. Retrieved 2013-07-27. "Welcome to KitePharma, Inc". kitepharma.com. Archived from the original on 2013-07-28. Retrieved...
£45.3 billion Shire deal as pharma M&A rolls on". May 9, 2018 – via uk.reuters.com. "FirstWord Lists – The 20 largest pharma M&Adeals". Gilbert, Daniel...
Approves Kite's Tecartus, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma" (Press release). KitePharma. 24 July 2020...
Approves Kite's Tecartus, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma" (Press release). KitePharma. 24 July 2020...
Solel BioLineRx Compugen D. Medical Industries Given Imaging Insightec KitePharma Perrigo Pluristem Therapeutics Rosetta Genomics Syneron Medical Taro...
good clinical response, and 70% had complete or near-complete response. KitePharma, Juno Therapeutics, Adaptimmune Therapeutics are active in the field...
refractory or has relapsed at least twice". Novartis. Retrieved 2019-01-30. "KitePharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation...
mutated non-small cell lung cancer Novartis KTE-X19 Mantle cell lymphoma KitePharma Selpercatinib RET fusion-positive non-small cell lung cancer Eli Lilly...
platform marketed by Singapore based Kyan Therapeutics in partnership with KitePharma and the National University of Singapore to provided personalized combination...
December 2014. "Despite Covid-19, fresh investments flowing into Gujarat's Pharma Sector". timesofindia.indiatimes.com. 14 March 2021. Archived from the original...
lost." "New Mexico Rancher's 'Flying Disk' Proves to Be Weather Balloon-Kite". Fort Worth Star-Telegram (Morning, 5 star ed.). Fort Worth, TX. July 9...
Global Information
